Search Results

Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice.

• Authors : Hu, Chunxiu; Wei, Heng; van den Hoek, Anita M.

• Source: PLoS ONE. May 17, 2011, Vol. 6 Issue 5, e19423.

Record details

Different Transcriptional Control of Metabolism and Extracellular Matrix in Visceral and Subcutaneous Fat of Obese and Rimonabant Treated Mice.

• Authors : Poussin, Carine; Hall, Diana; Minehira, Kaori

• Source: PLoS ONE. October 13, 2008, Vol. 3 Issue 10, e3385.

Record details

Rimonabant adds appetizing choice to slim obesity market.

• Authors : Wadman, Meredith

• Source: Nature Medicine. January, 2006, Vol. 12 Issue 1, p27, 1 p.

Record details

Tolerance and dependence to [DELTA].sup.9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.

• Authors : Wilkerson, Jenny L.; Schulze, David R.; McMahon, Lance R.

• Source: PLoS ONE. March 12, 2019, Vol. 14 Issue 3, e0209947.

Record details

Inhibitory effect of a weight-loss Chinese herbal formula RCM-107 on pancreatic [alpha]-amylase activity: Enzymatic and in silico approaches.

• Authors : Luo, Shiqi; Lenon, George Binh; Gill, Harsharn

• Source: PLoS ONE. April 29, 2020, Vol. 15 Issue 4, e0231815.

Record details

Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study.

• Authors : Chung, Hery; Fierro, Angélica; Pessoa-Mahana, C. David

• Source: PLoS ONE. July 23, 2019, Vol. 14 Issue 7, e0220025.

Record details

Patent Issued for Composition Containing Glibenclamide (USPTO 10,758,503).

• Source: Mental Health Weekly Digest. September 14, 2020, 782.

Record details

Patent Application Titled 'Use Of Mavoglurant In The Reduction Of Alcohol Use Or In Preventing Relapse Into Alcohol Use' Published Online (USPTO 20200237721).

• Source: Mental Health Weekly Digest. August 17, 2020, 895.

Record details

Reports Summarize Addiction Research Findings from West Virginia University (The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice).

• Source: Mental Health Weekly Digest. August 3, 2020, 534.

Record details

New Irritable Bowel Syndrome Findings Reported from Medical University of Lodz (Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists Suggest Their Potential Use In Irritable Bowel Syndrome With Constipation: a Systematic ...)

• Source: Mental Health Weekly Digest. January 6, 2020, 323.

Record details